Selexis to Participate at Several Upcoming Industry Conferences

GENEVA--()--Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today its planned participation at upcoming industry conferences, as follows:

BioProcess International Conference
25 – 28 September 2017, Hynes Convention Center, Boston, USA
Selexis will attend the conference and exhibit along with KBI Biopharma.
For more information, please visit: https://lifesciences.knect365.com/bioprocessinternational/

23rd Annual Partnering Conference BIO Europe
6 – 8 November 2017, CityCube Berlin, Berlin, Germany
Selexis will sponsor the conference and participate in the partnering program.
For more information, please visit: https://ebdgroup.knect365.com/bioeurope/

9th Annual PEGS Europe Protein & Engineering Summit
13 – 17 November 2017, EPIC SANA Lisboa Hotel, Lisbon, Portugal
Selexis Chief Scientific Officer Pierre-Alain Girod, PhD will present “Genome-Wide Signals Detection for Enhanced Cell Line Productivity and Stability” on Thursday, 16 November at 10:05 a.m. WET as part of the Expression track. Additionally, Selexis is a conference sponsor and exhibitor.
For more information, please visit: http://www.pegsummiteurope.com/

About Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 80+ drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.

 

FOR MORE INFORMATION

- Web

www.selexis.com

- LinkedIn

www.linkedin.com/company/selexis-sa

- Twitter

www.twitter.com/SelexisSA

- Facebook

www.facebook.com/SelexisSA

 

Contacts

Media Inquiries for Selexis
Sam Brown Inc.
Mike Beyer, +1 312-961-2502
mikebeyer@sambrown.com
or
Company Inquiries for Selexis
Robert Meister, +1 602-953-1716
Head, Corporate Communications
robert.meister@selexis.com

Contacts

Media Inquiries for Selexis
Sam Brown Inc.
Mike Beyer, +1 312-961-2502
mikebeyer@sambrown.com
or
Company Inquiries for Selexis
Robert Meister, +1 602-953-1716
Head, Corporate Communications
robert.meister@selexis.com